Alirinetide

Alirinetide (GM604) is an oligopeptide containing 6 amino acids. Alirinetide can cross the blood-brain barrier and can be used for the research of multiple neurodegenerative diseases[1].

Signaling Pathways >> Others >> Others

Research Areas >> Neurological Disease

Alirinetide (GM604) (0.1-10 mg/mL; 24 h) prevents SH-SY5Y cell death[1]. Alirinetide (48 h) predominantly represses Parkinson’s disease-associated genes in SH-SY5Y cells, these genes were largely associated with the mitochondrial protein complex and respiratory chain[1]. Cell Viability Assay[1] Cell Line: SH-SY5Y cells Concentration: 0.1, 1 or 10 mg/mL Incubation Time: 24 h Result: Led to dose-dependent rescue of cell survival, with complete recovery of cell viability at the highest dose (10 mg/mL).

Alirinetide (GM604) (0-20 mg/kg; i.v.; twice daily for 5 days) improves behavioral, biochemical, and histological features in the 6-OHDA mouse model[1]. Animal Model: C57BL/6 mice, 6-hydroxydopamine (6-OHDA) mouse model[1] Dosage: 0, 1, 5, 10 or 20 mg/kg Administration: Intravenous injection, twice daily for 5 days Result: Almost completely abrogated 6-OHDA effects at the highest dose, leading to improved motor performance, increased numbers of TH-positive neurons in the substantia nigra, and increased brain levels of dopamine, 3,4-Dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA).

[1]. Swindell W R, et al. GM604 for Parkinson's Disease treatment: Pre-clinical findings and results from a pilot placebo-controlled trial. F1000Research, 2017, 6.